John Muir Health, Concord Medical Center

December 27, 2024
John Muir Health, Concord Medical Center
Concord, CA
Type of Facility: Short Term Acute Care
Type of Control: Voluntary Non-profit
Total Staffed Beds: 244
Total Patient Revenue: $3,921,023,108
Total Discharges: 11,522
Total Patient Days: 58,403
LungVision® Acquisition: 2023
John Muir Health, Concord Medical Center

Prometheus Medical Innovations.
Director of the Thoracic Surgical Program, John Muir Health
LungVision® Trained: 2023
Background
Dr. Wilson Tsai had built a leading robotic-assisted thoracic surgery (RAS) program and was performing both a bulk of the navigational bronchoscopies to diagnose lung cancer as well as performing robotic lung resection on patients that either were definitively diagnosed with lung cancer or had a suspicious pulmonary nodule that had a high probability of cancer.
Dr. Tsai was seeking a real-time imaging solution that:
Augmented the capabilities of the Auris Monarch and later the Ion by Intuitive robotic bronchoscope to overcome CT-to-body divergence and maximize the likelihood of a definitive diagnosis, particularly on smaller lesions that might be early-stage cancer
Had a shallow learning curve so that the interventional pulmonology team at John Muir Health could take on more of the navigational bronchoscopy cases, enabling Dr. Tsai to focus on surgical resection
Seamlessly integrates into a technology-rich OR to streamline Dr. Tsai’s innovative SABRE (Single Anesthetic Bronchoscopic Robotic Event) protocol which involved robotic-assisted bronchoscopy (RAB) followed by a robotic lung resection in a single anesthesia event.
Acquired LungVision® in June, 2023.
Clinical and Financial Impact
Data provided by Wilson Tsai, MD


Takeaway
Utilizing LungVision® AI-driven real-time imaging paired with robotic bronchoscopy for more precise endobronchial lung nodule biopsy and ICG-soaked fiducial coil placement for subsequent wedge resection in cases of lung cancer diagnosis, Dr. Tsai was able to drive a 91% overall diagnostic yield.¹
Empowered by LungVision® real-time imaging to maximize likelihood of a definitive diagnosis via endobronchial lung nodule biopsy, the SABRE single-anesthesia event protocol enabled the thoracic surgery program to reduce average time to treatment (TTT) from 35 to 42 calendar days to 3 hours.²
Compared with using a Cios Spin as a 3D C-arm, the combination of Cios Spin as a 2D C-arm with LungVision’s proprietary AI-driven tomographic imaging algorithm was able to produce same if not better quality intraoperative tomographic imaging at < 1/5 the radiation spin-for-spin.¹